GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.
Broadly neutralizing Abs to HIV-1 are well described; however, identification of Ags that elicit these Abs has proven difficult. Persistent infection with GB virus type C (GBV-C) is associated with prolonged survival in HIV-1-infected individuals, and among those without HIV-1 viremia, the presence of Ab to GBV-C glycoprotein E2 is also associated with survival. GBV-C E2 protein inhibits HIV-1 entry, and an antigenic peptide within E2 interferes with gp41-induced membrane perturbations in vitro, suggesting the possibility of structural mimicry between GBV-C E2 protein and HIV-1 particles. Naturally occurring human and experimentally induced GBV-C E2 Abs were examined for their ability to neutralize infectious HIV-1 particles and HIV-1-enveloped pseudovirus particles. All GBV-C E2 Abs neutralized diverse isolates of HIV-1 with the exception of rabbit anti-peptide Abs raised against a synthetic GBV-C E2 peptide. Rabbit anti-GBV-C E2 Abs neutralized HIV-1-pseudotyped retrovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2 Abs immune-precipitated HIV-1 gag particles containing the vesicular stomatitis virus type G envelope, HIV-1 envelope, GBV-C envelope, or no viral envelope. The Abs did not neutralize or immune-precipitate mumps or yellow fever viruses. Rabbit GBV-C E2 Abs inhibited HIV attachment to cells but did not inhibit entry following attachment. Taken together, these data indicate that the GBV-C E2 protein has a structural motif that elicits Abs that cross-react with a cellular Ag present on retrovirus particles, independent of HIV-1 envelope glycoproteins. The data provide evidence that a heterologous viral protein can induce HIV-1-neutralizing Abs.
Mohr
Emma L
EL
Division of Infectious Diseases, Department of Internal Medicine, Iowa City Veterans Affairs Medical Center, Iowa City, IA 52242, USA.
Xiang
Jinhua
J
McLinden
James H
JH
Kaufman
Thomas M
TM
Chang
Qing
Q
Montefiori
David C
DC
Klinzman
Donna
D
Stapleton
Jack T
JT
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D002469:Cell Separation; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D029407:GB virus C / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D047468:Immunoprecipitation; D051379:Mice; D018716:Molecular Mimicry / Q000276:immunology; D011817:Rabbits; D014759:Viral Envelope Proteins / Q000276:immunology*; D014771:Virion / Q000276:immunology; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000276:immunology
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
J Virol. 2009 Oct;83(19):10211-23
19640992
Lancet. 2004 Jun 19;363(9426):2040-6
15207954
J Virol. 2005 Aug;79(16):10103-7
16051803
Science. 1996 Jan 26;271(5248):505-8
8560265
J Clin Microbiol. 1984 Jan;19(1):21-5
6361060
Vaccine. 2003 Jul 28;21(24):3370-3
12850342
J Infect Dis. 2005 Mar 1;191(5):678-85
15688280
J Virol. 1998 May;72(5):4541-5
9557757
J Virol. 1998 Aug;72(8):6520-6
9658095
AIDS. 2008 Nov 12;22(17):2398-400
18981782
HIV Med. 2006 Apr;7(3):173-80
16494631
J Clin Immunol. 1988 Nov;8(6):464-72
3146584
J Mol Biol. 2004 Apr 23;338(2):311-27
15066434
J Infect Dis. 2008 May 15;197(10):1369-77
18419578
J Leukoc Biol. 2005 Dec;78(6):1198-203
16204638
AIDS Res Hum Retroviruses. 1993 Nov;9(11):1051-3
8312047
Nature. 2010 Mar 11;464(7286):161-2
20220821
J Clin Microbiol. 2004 Sep;42(9):3915-9
15364968
AIDS Res Hum Retroviruses. 2010 Mar;26(3):279-91
20218881
Science. 2005 Jun 24;308(5730):1906-8
15860590
N Engl J Med. 2008 Aug 28;359(9):888-90
18753644
Curr Opin HIV AIDS. 2009 Sep;4(5):400-7
20048704
AIDS. 2007 Mar 12;21(5):645-7
17314528
Luminescence. 2005 Jul-Oct;20(4-5):279-81
16134194
J Immunol. 2000 Mar 15;164(6):3426-33
10706739
J Viral Hepat. 2009 Nov;16(11):757-68
19758271
Vox Sang. 1998;74(3):161-7
9595643
HIV Med. 2007 Nov;8(8):561-7
17944690
J Virol Methods. 2008 Jul;151(1):40-6
18501437
J Virol Methods. 2003 Jun 30;110(2):185-91
12798247
J Phys Chem B. 2009 May 21;113(20):7383-91
19402654
FEBS Lett. 2006 Apr 17;580(9):2395-99
16616522
J Infect Dis. 2006 Feb 1;193(3):451-4
16388494
J Virol. 2000 Oct;74(19):9125-33
10982359
J Infect Dis. 1999 Apr;179(4):783-9
10068572
FASEB J. 2008 Dec;22(12):4338-51
18776068
FEBS Lett. 2008 Nov 12;582(27):3798-804
18930052
N Engl J Med. 2001 Sep 6;345(10):707-14
11547739
Virology. 2008 Jun 5;375(2):315-20
18367229
AIDS. 2003 Feb 14;17(3):301-9
12556683
N Engl J Med. 2004 Mar 4;350(10):981-90
14999110
J Virol. 2003 May;77(10):5902-10
12719583
J Med Microbiol. 2009 May;58(Pt 5):638-643
19369526
AIDS. 2010 Jan 2;24(1):35-43
19779318
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
7520721
PLoS One. 2009;4(2):e4505
19229336
J Interferon Cytokine Res. 2005 May;25(5):261-70
15871663
Virology. 1996 Nov 15;225(2):282-92
8918914
AIDS. 2007 May 11;21(8):1045-8
17457101
N Engl J Med. 2001 Sep 6;345(10):715-24
11547740
Science. 2008 Jul 25;321(5888):530-2
18653883
Vaccine. 1999 Mar 26;17(13-14):1700-5
10194825
J Clin Microbiol. 2000 Aug;38(8):3055-60
10921977
J Virol. 2000 Nov;74(21):10055-62
11024134
AIDS. 2009 Jan 28;23(3):329-33
19114861
J Infect Dis. 1999 Sep;180(3):871-5
10438383
Semin Liver Dis. 2003 May;23(2):137-48
12800067
J Virol. 2006 Dec;80(24):12131-40
17035329
Biochim Biophys Acta. 2009 Mar;1788(3):660-5
19100711
Immunity. 2008 Jan;28(1):10-2
18199412
J Virol. 2010 Feb;84(3):1631-6
19923174
Hepatology. 1997 Dec;26(6):1626-33
9398008
Arch Biochem Biophys. 2005 Oct 15;442(2):149-59
16165082
AIDS. 2009 Oct 23;23(16):2069-77
19710597
Nat Med. 1995 Jun;1(6):564-9
7585124